Stanford researchers have developed an LVCTM3 system for producing lentiviral vectors and other viral particles, offering a cost-effective, simplified and scalable solution for various applications from gene therapy to vaccine development.
Current challenges in corneal endothelial cells (CEC) transplantation include the limited availability of donor grafts and the inability of CECs to regenerate within the body.
Researchers at Stanford University have found that recombinant osteopontin (SPP1) protein reduces foreign body response (FBR) and thereby facilitates successful integration and function of implantable devices.
Elastin-like polypeptides (ELPs) are promising biomaterials for medical applications due to their non-immunogenicity, scalable synthesis, and tunable self-assembly.
The lack of effective treatments for myocardial ischemia and reperfusion injury has been a major challenge in decreasing mortality rates from myocardial infarctions. Stromal cell-derived factor-1?
Early detection of ovarian cancer is crucial, with a 5-year survival rate exceeding 90%. Once this early window has been missed, the 5-year survival rate precipitously drops below 50%.
Researchers at Stanford University have developed a novel platform for genetically engineering cells within a living organism, circumventing previous limitations related to accessing target tissues and the size of the genetic payload.
Researchers at Stanford have combined 3D printing and pyrolysis to produce a robust and biocompatible high resolution micro-array patch (MAP) for transdermal drug delivery.
Different drug delivery agents, including synthetic polymers, virus-based vectors, lipid-based vectors, and extracellular vesicles (EVs), have been explored previously.
Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Researchers at Stanford University have formulated a novel biomaterial suitable for three-dimensional (3D) bioprinting: a homogeneous composite of polycaprolactone (PCL), gelatin, and beta-tricalcium phosphate.
Stanford researchers have developed a high-sensitivity cell-based assay for predicting the innate immune response to recombinant adeno-associated virus.
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Researchers at Stanford have facilitated active agent passage across the blood-brain barrier (BBB) by conjugating the active agent with a plasma protein that gets taken up by microglia.